Rapid Micro Biosystems Analyst Ratings
Rapid Micro Biosystems Analyst Ratings
While ratings are subjective and will change, the latest Rapid Micro Biosystems (RPID) rating was a downgraded with a price target of $0.00 to $0.00. The current price Rapid Micro Biosystems (RPID) is trading at is $3.83, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/11/2022 | 108.88% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
| 03/07/2022 | 161.1% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 02/15/2022 | 187.21% | Morgan Stanley | $24 → $11 | Maintains | Equal-Weight |
| 11/15/2021 | 526.63% | Morgan Stanley | $26 → $24 | Maintains | Equal-Weight |
| 08/09/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/09/2021 | 578.85% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
| 08/09/2021 | 631.07% | Stifel | → $28 | Initiates Coverage On | → Buy |
| 08/09/2021 | 683.29% | JP Morgan | → $30 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/16/2022 | — | 摩根大通 | 降级 | 超重 → 中性 | |
| 05/11/2022 | 108.88% | 摩根士丹利 | 10 美元 → 8 美元 | 维护 | 重量相等 |
| 03/07/2022 | 161.1% | 摩根士丹利 | 11 美元 → 10 美元 | 维护 | 重量相等 |
| 2022 年 2 月 15 日 | 187.21% | 摩根士丹利 | 24 美元 → 11 美元 | 维护 | 重量相等 |
| 11/15/2021 | 526.63% | 摩根士丹利 | 26 美元 → 24 美元 | 维护 | 重量相等 |
| 2021 年 9 月 8 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 2021 年 9 月 8 日 | 578.85% | 摩根士丹利 | → 26 美元 | 启动覆盖范围开启 | → 重量相等 |
| 2021 年 9 月 8 日 | 631.07% | Stifel | → 28 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 9 月 8 日 | 683.29% | 摩根大通 | → 30 美元 | 启动覆盖范围开启 | → 超重 |
Rapid Micro Biosystems Questions & Answers
快速微生物系统问题与解答
The latest price target for Rapid Micro Biosystems (NASDAQ: RPID) was reported by JP Morgan on August 16, 2022. The analyst firm set a price target for $0.00 expecting RPID to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
摩根大通于2022年8月16日公布了快速微生物系统（纳斯达克股票代码：RPID）的最新目标股价。该分析公司将目标股价定为0.00美元，预计RPID将在12个月内降至12个月内（可能下跌-100.00％）。去年有5家分析公司公布了评级。
The latest analyst rating for Rapid Micro Biosystems (NASDAQ: RPID) was provided by JP Morgan, and Rapid Micro Biosystems downgraded their neutral rating.
摩根大通对快速微生物系统（纳斯达克股票代码：RPID）的最新分析师评级由摩根大通提供，而Rapid Micro Biosystems下调了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rapid Micro Biosystems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rapid Micro Biosystems was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Rapid Micro Biosystems的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Rapid Micro Biosystems的最新评级是在2022年8月16日发布的，因此您应该预计下一个评级将在2023年8月16日左右公布。
While ratings are subjective and will change, the latest Rapid Micro Biosystems (RPID) rating was a downgraded with a price target of $0.00 to $0.00. The current price Rapid Micro Biosystems (RPID) is trading at is $3.83, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的快速微生物系统（RPID）评级已下调，目标股价为0.00美元至0.00美元。Rapid Micro Biosystems（RPID）目前的交易价格为3.83美元，超出了分析师的预期区间。
